Definium Therapeutics (NASDAQ:DFTX) Announces Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Definium Therapeutics (NASDAQ:DFTX) announced its earnings results on Monday. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.09, FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• DT120 delivered positive Phase III results in GAD and MDD across three studies, with rapid, durable improvements and generally good tolerability. The results earned the program FDA breakthrough therapy designations in both indications.
• Definium remains on track to file an NDA for DT120 in the first half of 2027 and is preparing for a potential launch. However, the company did not disclose details of its FDA meeting or its filing strategy for MDD, where a second Phase III study, Ascend, is still underway.
• The company reported approximately $1.05 billion in cash, equivalents, and investments at quarter-end, which it expects to fund operations into 2030. R&D and G&A expenses increased year over year as Definium expanded development and commercial-readiness efforts.
• Early DT402 results in autism spectrum disorder showed improvements across several social and functional measures, prompting the company to stop enrollment after five participants and plan a multi-day dosing study for 2027. The findings are preliminary, coming from a small, open-label study.
• Definium is developing its supervised-treatment launch infrastructure and cited payer feedback indicating a potential pricing corridor of $30,000 to $75,000. Management said more payer discussions are needed to narrow that range and emphasized that provider readiness, access, and patient support will be important to adoption.

Definium Therapeutics Stock Up 6.4%

NASDAQ DFTX traded up $2.12 on Monday, hitting $35.39. 1,414,317 shares of the company were exchanged, compared to its average volume of 2,224,688. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The company has a market cap of $4.76 billion, a PE ratio of -10.32 and a beta of 2.23. The stock has a fifty day moving average of $36.60 and a 200-day moving average of $29.95. Definium Therapeutics has a 12 month low of $10.46 and a 12 month high of $49.70.

Insider Activity at Definium Therapeutics

In other news, insider Mark Sullivan sold 14,051 shares of the stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $513,845.07. Following the transaction, the insider owned 494,228 shares of the company’s stock, valued at $18,073,917.96. This represents a 2.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the firm’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the sale, the chief financial officer owned 394,528 shares of the company’s stock, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 71,098 shares of company stock valued at $2,626,115. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DFTX. Wellington Management Group LLP acquired a new stake in Definium Therapeutics in the second quarter valued at approximately $138,755,000. Russell Investments Group Ltd. raised its position in shares of Definium Therapeutics by 116.1% during the third quarter. Russell Investments Group Ltd. now owns 331,702 shares of the company’s stock worth $12,647,000 after purchasing an additional 178,225 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Definium Therapeutics during the second quarter worth approximately $6,992,000. Moody Aldrich Partners LLC lifted its holdings in shares of Definium Therapeutics by 191.8% in the 3rd quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock worth $5,666,000 after purchasing an additional 97,845 shares in the last quarter. Finally, Lisanti Capital Growth LLC acquired a new position in Definium Therapeutics during the 3rd quarter valued at about $2,647,000. Institutional investors own 27.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on DFTX shares. Oppenheimer restated an “outperform” rating and set a $75.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. UBS Group restated a “buy” rating and issued a $70.00 price target on shares of Definium Therapeutics in a research report on Tuesday, September 15th. Finally, Bank of America initiated coverage on shares of Definium Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $66.00.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.